Back
 JCT  Vol.5 No.14 , December 2014
Causes and Stages of Hepatocellular Carcinoma at Patient Presentation at a Tertiary Medical Center in Western Saudi Arabia
Abstract: Background: With 748,300 new cases diagnosed every year, hepatocellular carcinoma (HCC) is the 5th and the 7th most common cancer among males and females, respectively, and causes 7% of all cancer-related deaths. HCC represents more than 90% of primary liver cancers. Objective: The aim of the present study was to recognize the stages of HCC at presentation in patients who were diagnosed at King Abdul Aziz University Hospital (KAUH) and to identify the associated laboratory features of advance HCC. Materials and Methods: A retrospective analysis of 57 HCC patients admitted to KAUH between January 2008 and December 2012 was conducted. The diagnosis was established using ultrasound (U/S), computed tomography (CT) and/or magnetic resonance imaging (MRI), with or without a liver biopsy, as well as blood testing for alpha-fetoprotein. The following data were extracted from the medical records at KAUH: patient demographics (age, sex and nationality), laboratory results (CBC, LFT, PT, INR and alpha-fetoprotein), radiological results, biopsy results for those patients who underwent biopsy, outcomes (living, deceased or lost from the follow-up), and mortality and survival rates. Results: A total of 57 HCC patients were admitted during the study period, and 3 patients were excluded from the analysis. Of the remaining 54 patients, 44 (81.5%) were males and 10 (18.5%) were females. The mean age was 64.54 years (SD, 11.2 years; range, 31 - 86 years). The majority of patients were Saudis (19, 35.2%), non-Saudis (35, 64.8%), Egyptians (9, 16.6%) and Yemenis (7, 13%). The remaining 19 (35.2%) patients comprised other nationalities. Chronic hepatitis C virus was the most common cause for liver cirrhosis (35 patients, 64.8%). CT was the primary diagnostic method (37 patients 68.5%), while 9 (16.7%) cases were confirmed by adnominal MRI. Six patients (11.1%) were diagnosed with abdominal ultrasound examination and elevated alpha-fetoprotein levels. In 2 (3.7%) patients, HCC was confirmed by liver biopsy. The majority of the patients (37, 68.5%) had advanced disease. Only 21 (39%) patients underwent radio frequency appellation (RFA). The mean survival time from diagnosis to death was 5.9 months (SD, 5.7 months), and the longest survival time to death was 20 months. Conclusion: The majority of our patients presented at an advanced disease stage, and CHC was the most common underlying cause for liver cirrhosis in our cohort of HCC patients. The proper implementation of HCC screening programs for cirrhotic patients is expected to help detect the treatable stages of HCC in a timely manner.
Cite this paper: Alkhayyat, S. , Fallatah, H. , Akbar, H. , Al Ahwal, M. and Al Ghamdi, W. (2014) Causes and Stages of Hepatocellular Carcinoma at Patient Presentation at a Tertiary Medical Center in Western Saudi Arabia. Journal of Cancer Therapy, 5, 1303-1310. doi: 10.4236/jct.2014.514130.
References

[1]   Jemal, A., Bray, F., Center, M.M., Ferly, J., Ward, E. and Forman, D. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90. http://dx.doi.org/10.3322/caac.20107

[2]   Kanavos, P. (2006) The Rising Burden of Cancer in the Developing World. Annals of Oncology, 17, viii15-viii23.

[3]   European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 56, 908-943.

[4]   Al-Faleh, F.Z., Al-Jeffri, M., Ramia, S., Al-Rashed, R., Arif, M., Rezeig, M., Al-Toraif, I., Baksh, M., Mishkkhas, A., Makki, O., Al-Freihi, H., Mirdad, S., Al-Juma, A, Yasin, T., Al-Swailem, A. and Ayoola, A. (1999) Seroepidemiology of Hepatitis B Infection in Saudi Children 8 Years after a Mass Hepatitis B Vaccination Programme. Journal of Infection, 38, 167-170.
http://dx.doi.org/10.1016/S0163-4453(99)90245-1

[5]   Koriech, O.M. and Al-Kuhaymi R. (1994) Profile of Cancer in Riyadh Armed Forces Hospital. Annals of Saudi Medicine, 14, 187-194.

[6]   Al-Eid, H.S. and Garcia, A.D. (2014) Cancer Incidence Report Saudi Arabia 2009.
http://www.scr.org.sa/

[7]   Al-Faleh, F.Z., Al-Shehri, S., Al-Ansari, S., Al-Jeffri, M., Al-Mazrou, Y., Shaffi, A. and Abdo, A.A. (2008) Long-Term Protection of Hepatitis B Vaccine 18 Years after Vaccination. Journal of Infection, 57, 404-409.

[8]   Al Ghamdi, S.S., Fallatah, H.I., Fetyani, D.M., Al-Mughales, J.A. and Gelaidan, A.T. (2013) Long-Term Efficacy of the Hepatitis B Vaccine in a High-Risk Group. Journal of Medical Virology, 85, 1518-1512. http://dx.doi.org/10.1002/jmv.23658

[9]   Alswat, K.A., Sanai, F.M., Altuwaijri, M., Albenmousa, A., Almadi, M., Al-Hamoudi, W.K., and Abdo, A.A. (2013) Clinical Characteristics of Patients with Hepatocellular Carcinoma in a Middle Eastern Population. Hepatitis Monthly, 13, e7612. http://dx.doi.org/10.5812/hepatmon.7612

[10]   Madani, T.A. (2007) Hepatitis C Virus Infections Reported in Saudi Arabia over 11 Years of Surveillance. Annals of Saudi Medicine, 27, 191-194. http://dx.doi.org/10.4103/0256-4947.51500

[11]   Akbar, H.O., Al Ghamdi, A., Qattan, F., Fallatah, H.I. and Al Rumani, M. (2012) Chronic Hepatitis C in Saudiarabia: Three Years Local Experience in a University Hospital. Hepatitis Monthly, 12, e6178. http://dx.doi.org/10.5812/hepatmon.6178

[12]   Trevisani, F., D’Intino, P.E., Caraceni, P., Pizzo, M., Stefanini, G.F., Mazziotti, A., Grazi, G.L., Gozzetti, G., Gasbarrini, G. and Bernardi, M. (1995) Etiologic Factors and Clinical Presentation of Hepatocellular Carcinoma. Differences between Cirrhotic and Noncirrhotic Italian Patient. Cancer, 75, 2220-2232. http://dx.doi.org/10.1002/1097-0142(19950501)75:9<2220::AID-CNCR2820750906>3.0.CO;2-4

[13]   Di Bisceglie, A.M. (2002) Epidemiology and Clinical Presentation of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 13, S169-S171.
http://dx.doi.org/10.1016/S1051-0443(07)61783-7

[14]   Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A. and Gennari, L. (1996) Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. The New England Journal of Medicine, 334, 693-700. http://dx.doi.org/10.1056/NEJM199603143341104

[15]   Llovet, J.M., Brú, C. and Bruix, J. (1999) Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. Seminars in Liver Disease, 19, 329-338. http://dx.doi.org/10.1055/s-2007-1007122

[16]   Yao, F.Y., Ferrell, L., Bass, N.M., Bacchetti, P., Ascher, N.L. and Roberts, J.P. (2002) Liver Transplantation for Hepatocellular Carcinoma: Comparison of the Proposed UCSF Criteria with the Milan Criteria and the Pittsburgh Modified TNM Criteria. Liver Transplantation, 8, 765-774.
http://dx.doi.org/10.1053/jlts.2002.34892

[17]   Bruix, J. and Sherman, M. (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology, 53, 1020-1022. http://dx.doi.org/10.1002/hep.24199

[18]   Ioannou, G.N., Splan, M.F., Weiss, N.S., McDonald, G.B., Beretta, L. and Lee, S.P. (2007) Incidence and Predictors of Hepatocellular Carcinoma in Patients with Cirrhosis. Clinical Gastroenterology and Hepatology, 5, 938-945.

[19]   Mughal, T.I. and Patel, S.B. (1996) Hepatocellular Carcinoma: A Review of 140 Cases. Annals of Saudi Medicine, 16, 53-55.

[20]   Alsohaibani, F., Porter, G., Al-Ashgar, H., Walsh, M., Berry, R., Molinari, M. and Peltekian, K.M. (2011) Comparison of Cancer Care for Hepatocellular Carcinoma at Two Tertiary-Care Referral Centers from High and Low Endemic Regions for Viral Hepatitis. Journal of Gastrointestinal Cancer, 42, 228-235. http://dx.doi.org/10.1007/s12029-010-9200-x

[21]   Nouh, M.S., Bashi, S.A., Laajam, M.A., Mofleh, I.A. and Al-Aska, A. (1990) Hepatitis B Virus vs Schistosomiasis and Hepatocellular Carcinoma in Saudi Arabia. East African Medical Journal, 67, 139-145.

[22]   Ayoola, E.A. and Gadour, M.O. (2004) Hepatocellular Carcinoma in Saudi Arabia: Role of Hepatitis B and C Infection. Journal of Gastroenterology and Hepatology, 19, 665-669.
http://dx.doi.org/10.1111/j.1440-1746.2003.03334.x

[23]   Herbst, D.A. and Reddy, K.R. (2012) Risk Factors for Hepatocellular Carcinoma. Clinical Liver Disease, 1, 180-182. http://dx.doi.org/10.1002/cld.111

[24]   Tan, C.H., Low, S.C. and Thng, C.H. (2011) APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. International Journal of Hepatology, 2011, Article ID: 519783. http://dx.doi.org/10.4061/2011/519783

[25]   Sersté, T., Barrau, V., Ozenne, V., Vullierme, M.P., Bedossa, P., Farges, O., Valla, D.C., Vilgrain, V., Paradis, V. and Degos, F. (2012) Accuracy and Disagreement of Computed Tomography and Magnetic Resonance Imaging for the Diagnosis of Small Hepatocellular Carcinoma and Dysplastic Nodules: Role of Biopsy. Hepatology, 55, 800-806. http://dx.doi.org/10.1002/hep.24746

[26]   Abdo, A.A., Hassanain, M., AlJumah, A., AlOlayan, A., Sanai, F.M., Alsuhaibani, H.A., Abdulkareem, H., Abdallah, K., AlMuaikeel, M., Al Saghier, M., Babatin, M., Kabbani, M., Bazarbashi, S., Metrakos, P. and Bruix, J., Saudi Association for the Study of Liver Diseases and Transplantation, Saudi Oncology Society (2012) Saudi Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Technical Review and Practice Guidelines. Annals of Saudi Medicine, 32, 174-199.

[27]   Lu, S.N., Wang, J.H., Liu, S.L., Hung, C.H., Chen, C.H., Tung, H.D., Chen, T.M., Huang, W.S., Lee, C.M., Chen, C.C. and Changchien, C.S. (2006) Thrombocytopenia as a Surrogate for Cirrhosis and a Marker for the Identification of Patients at High-Risk for Hepatocellular Carcinoma. Cancer, 107, 2212-2222.

[28]   Kubo, S., Tanaka, H., Shuto, T., Takemura, S., Yamamoto, T., Uenishi, T., Tanaka, S., Ogawa, M., Sakabe, K., Yamazaki, K. and Hirohashi, K. (2004) Correlation between Low Platelet Count and Multicentricity of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C. Hepatology Research, 30, 221-225. http://dx.doi.org/10.1016/j.hepres.2004.10.005

[29]   Fallatah, H. (2014) Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology, 2014, Article ID: 357287. http://dx.doi.org/10.1155/2014/357287

[30]   Cabrera, R. (2012) Systemic Targeted Therapy beyond Sorafenib. Clinical Liver Disease, 1, 212-216. http://dx.doi.org/10.1002/cld.128

[31]   Shiina, S., Tateishi, R., Arano, T., Uchino, K., Enooku, K., Nakagawa, H., Asaoka, Y., Sato, T., Masuzaki, R., Kondo, Y., Goto, T., Yoshida, H., Omata, M. and Koike, K. (2012) Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. The American Journal of Gastroenterology, 107, 569-577. http://dx.doi.org/10.1038/ajg.2011.425

[32]   Duvoux, C., Roudot-Thoraval, F., Decaens, T., Pessione, F., Badran, H., Piardi, T., Francoz, C., Compagnon, P., Vanlemmens, C., Dumortier, J., Dharancy, S., Gugenheim, J., Bernard, P.H., Adam, R., Radenne, S., Muscari, F., Conti, F., Hardwigsen, J., Pageaux, G.P., Chazouillères, O., Salame, E., Hilleret, M.N., Lebray, P., Abergel, A., Debette-Gratien, M., Kluger, M.D., Mallat, A., Azoulay, D. and Cherqui, D., Liver Transplantation French Study Group (2012) Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan criteria. Gastroenterology, 143, 986-994. http://dx.doi.org/10.1053/j.gastro.2012.05.052

[33]   Papatheodoridis, G.V., Chrysanthos, N., Savvas, S., Sevastianos, V., Kafiri, G., Petraki, K. and Manesis, E.K. (2006) Diabetes Mellitus in Chronic Hepatitis B and C: Prevalence and Potential Association with the Extent of Liver Fibrosis. Journal of Viral Hepatitis, 13, 303-310.
http://dx.doi.org/10.1111/j.1365-2893.2005.00677.x

[34]   Al-Nozha, M.M., Al-Maatouq, M.A., Al-Mazrou, Y.Y., Al-Harthi, S.S., Arafah, M.R., Khalil, M.Z., Khan, N.B., Al-Khadra, A., Al-Marzouki, K., Nouh, M.S., Abdullah, M., Attas, O., Al-Shahid, M.S. and Al-Mobeireek, A. (2004) Diabetes Mellitus in Saudi Arabia. Saudi Medical Journal, 25, 1603-1610.

[35]   Abbas, Z., Siddiqui, A.U., Luck, N.H., Hassan, M., Mirza, R., Naqvi, A. and Rizvi, A.H. (2008) Prognostic Factors of Survival in Patients with Non-Resectable Hepatocellular Carcinoma: Hepatitis C versus Miscellaneous Etiology. Jour- nal of Pakistan Medical Association, 58, 602-607.

[36]   Yaghi, C., Sharara, A.I., Rassam, P., Moucari, R., Honein, K., BouJaoude, J., Slim, R., Noun, R., Abdul-Baki, H., Khalifeh, M., Ramia, S. and Sayegh, R. (2006) Hepatocellular Carcinoma in Lebanon: Etiology and Prognostic Factors Associated with Short-Term Survival. World Journal of Gastroenterology, 12, 3575-3580.

[37]   Paranaguá-Vezozzo, D.C., Ono, S.K., Alvarado-Mora, M.V., Farias, A.Q., Cunha-Silva, M., Fran?a, J.I., Alves, V.A., Sherman, M. and Carrilho, F.J. (2014) Epidemiology of HCC in Brazil: Incidence and Risk Factors in a Ten-Year Cohort. Annals of Hepatology, 13, 386-393.

[38]   Tateishi, R., Okanoue, T., Fujiwara, N., Okita, K., Kiyosawa, K., Omata, M., Kumada, H., Hayashi, N. and Koike, K. (2014) Clinical Characteristics, Treatment, and Prognosis of Non-B, Non-C Hepatocellular Carcinoma: A Large Retrospective Multicenter Cohort Study. Journal of Gastroenterology. (Published Online).
http://download.springer.com/static/pdf/32/art%253A10.1007%252Fs00535-014-0973-8.pdf?auth66=1413305494_df9385b19aa7645df3d09fef19f61057&ext=.pdf

[39]   Utsunomiya, T., Shimada. M., Kudo, M., Ichida, T., Matsui, O., Izumi, N., Matsuyama, Y., Sakamoto, M., Nakashima, O., Ku, Y., Kokudo, N. and Makuuchi, M., Liver Cancer Study Group of Japan (2014) Nationwide Study of 4741 Patients with Non-B Non-C Hepatocellular Carcinoma with Special Reference to the Therapeutic Impact. Annals of Surgery, 259, 336-345.
http://dx.doi.org/10.1097/SLA.0b013e31829291e9

 
 
Top